Sacituzumab govitecan response in extensive leptomeningeal carcinomatosis from triple-negative breast cancer: a case report

Autor: Jesús Yaringaño, María Roca-Herrera, Simeón Eremiev, Pau Mascaró-Baselga, Pau Benito, Fidel Núñez, Sergi Benavente, Isabel Pimentel

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate (ADC), was the first ADC approved for patients with metastatic triple-negative breast cancer (mTNBC) who had received at least two prior lines of therapy for advanced disease. Alth

Externí odkaz: https://doaj.org/article/a76af0ab0d714185970966c3be5c38a3

1742P Factors influencing awareness of patient associations in sarcoma: A multicentric cross-sectional study.

Autor: Mascaró Baselga, P.¹ (AUTHOR), Villacampa, G.² (AUTHOR), Navarro Garces, V.² (AUTHOR), Sebio Garcia, A.³ (AUTHOR), Alvarez, R.M.⁴ (AUTHOR), Sala Gonzalez, M.A.⁵ (AUTHOR), Marquina Ospina, G.⁶ (AUTHOR), Martinez Trufero, J.⁷ (AUTHOR), Cano, J.M.⁸ (AUTHOR), Redondo, A.⁹ (AUTHOR), Molina Diaz, A.¹⁰ (AUTHOR), Vega Cano, K.S.¹ (AUTHOR), Salva de Torres, C.¹ (AUTHOR), Yaringaño Cerna, J.G.¹ (AUTHOR), Martínez-Albaladejo, P.¹ (AUTHOR), de Torner Vidal, A.¹ (AUTHOR), Cicala, C.M.¹ (AUTHOR), Tabernero, J.¹ (AUTHOR), Valverde Morales, C.M.¹ (AUTHOR), Serrano, C.¹ (AUTHOR)

Publikováno v: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS1041-S1042. 2p.